Syndecan-3 (SDC3) is a member of the syndecan family of cell-surface molecules. It has diverse biological roles, participating in processes like angiogenesis, inflammation, and neural-related functions [2]. In the context of muscle stem cells, it modulates the INSR/AKT/mTOR pathway, acting as a regulator of myogenesis to prevent premature differentiation [7].

In Alzheimer's disease (AD), SDC3 was found to be differentially expressed in cholinergic SN56 cells carrying the Swedish APP (APPSWE) mutation. Knockdown of SDC3 attenuated oxidative stress-induced cell death in these cells, suggesting it mediates the specific effects of APPSWE on cholinergic neurodegeneration in AD [1]. In apparent treatment-resistant hypertension (aTRH), a genome-wide association study identified a novel association between SDC3 and aTRH, with lower expression of SDC3 in aTRH patients [3]. In ovarian cancer, lncRNA TRPM2-AS promotes cancer progression and cisplatin resistance by sponging miR-138-5p to release SDC3 mRNA [4]. In renal cell carcinoma, circRNA SCARB1 promotes cancer progression via the miR-510-5p/SDC3 axis [5]. In melanoma, LINC01116 facilitates progression by sequestering miR-3612 and up-regulating SDC3 [6].

In summary, SDC3 is involved in multiple biological processes and disease conditions. Studies, including those using gene-knockdown models, have revealed its role in neurodegeneration, hypertension, and several types of cancers. Understanding SDC3's functions in these contexts may provide potential therapeutic targets for the related diseases.